Abbott lowers earnings forecast after $21B Exact Sciences buy

Leave a Comment / By /

CEO Robert Ford said the companies are a good cultural fit and he expects demand for Exact’s colon cancer screening test to increase.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top